Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Immunotherapy and radiation in glioblastoma JOURNAL OF NEURO-ONCOLOGY Sahebjam, S., Sharabi, A., Lim, M., Kesarwani, P., Chinnaiyan, P. 2017; 134 (3): 531–39

Abstract

Radiation therapy plays a central role in the management of glioblastoma. Although primarily thought of as modality to provide local tumor control through DNA damage, the capacity of ionizing radiation to modulate tumor immune response has long been recognized. The recent emergence of clinically active immunotherapies offers exciting potential for harnessing the immune modulatory effects or radiation through combinatorial strategies designed to enhance clinical outcomes. In this Review, we provide background describing the unique immune environment within the central nervous system, how ionizing radiation may modulate the tumor immune response, preclinical and clinical data testing the combination of radiation and immune modulating agents, and highlight some of the current challenges in extending these findings clinically.

View details for DOI 10.1007/s11060-017-2413-0

View details for Web of Science ID 000411370700008

View details for PubMedID 28567588